Winslow Asset Management Inc. Sells 594 Shares of Eli Lilly and Company (NYSE:LLY)

Winslow Asset Management Inc. cut its position in Eli Lilly and Company (NYSE:LLY) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 40,541 shares of the company’s stock after selling 594 shares during the period. Eli Lilly and Company makes up approximately 4.1% of Winslow Asset Management Inc.’s portfolio, making the stock its 4th largest position. Winslow Asset Management Inc.’s holdings in Eli Lilly and Company were worth $19,013,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Silicon Valley Capital Partners acquired a new stake in Eli Lilly and Company during the first quarter worth about $25,000. Laffer Tengler Investments acquired a new stake in Eli Lilly and Company during the first quarter worth about $33,000. Raleigh Capital Management Inc. grew its holdings in Eli Lilly and Company by 156.4% during the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after acquiring an additional 61 shares during the period. Activest Wealth Management acquired a new stake in Eli Lilly and Company during the second quarter worth about $40,000. Finally, Riggs Asset Managment Co. Inc. grew its holdings in Eli Lilly and Company by 50.4% during the first quarter. Riggs Asset Managment Co. Inc. now owns 179 shares of the company’s stock worth $61,000 after acquiring an additional 60 shares during the period. 81.38% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wells Fargo & Company increased their price target on Eli Lilly and Company from $615.00 to $650.00 and gave the stock an “overweight” rating in a research report on Monday, October 9th. Truist Financial increased their price target on Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Argus increased their price target on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 price target on shares of Eli Lilly and Company in a research report on Monday, October 23rd. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $557.00.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,378 shares in the company, valued at $2,939,130.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the sale, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at approximately $2,939,130.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and Company stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total value of $130,169,600.00. Following the sale, the insider now directly owns 99,768,810 shares of the company’s stock, valued at $60,404,028,326.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 700,916 shares of company stock valued at $20,970,455,882. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 1.1 %

Shares of NYSE LLY opened at $597.71 on Friday. Eli Lilly and Company has a twelve month low of $309.20 and a twelve month high of $629.97. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. The stock has a fifty day simple moving average of $574.81 and a 200-day simple moving average of $502.26. The stock has a market capitalization of $567.41 billion, a PE ratio of 108.28, a PEG ratio of 3.74 and a beta of 0.33.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $1.13 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company’s payout ratio is presently 81.88%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.